Literature DB >> 27585560

Interaction between subclinical doses of the Parkinson's disease associated gene, α-synuclein, and the pesticide, rotenone, precipitates motor dysfunction and nigrostriatal neurodegeneration in rats.

Carol Naughton1, Daniel O'Toole2, Deniz Kirik3, Eilís Dowd4.   

Abstract

In most patients, Parkinson's disease is thought to emerge after a lifetime of exposure to, and interaction between, various genetic and environmental risk factors. One of the key genetic factors linked to this condition is α-synuclein, and the α-synuclein protein is pathologically associated with idiopathic cases. However, α-synuclein pathology is also present in presymptomatic, clinically "normal" individuals suggesting that environmental factors, such as Parkinson's disease-linked agricultural pesticides, may be required to precipitate Parkinson's disease in these individuals. In this context, the aim of this study was to assess the behavioural and neuropathological impact of exposing rats with a subclinical load of α-synuclein to subclinical doses of the organic pesticide, rotenone. Rats were randomly assigned to two groups for intra-nigral infusion of AAV2/5-GFP or AAV2/5-α-synuclein. Post viral motor function was assessed at 8, 10 and 12 weeks in the Corridor, Stepping and Whisker tests of lateralised motor function. At week 12, animals were performance-matched to receive a subsequent intra-striatal challenge of the organic pesticide rotenone (or its vehicle) to yield four final groups (Control, Rotenone, AAV2/5-α-synuclein and Combined). Behavioural testing resumed one week after rotenone surgery and continued for 5 weeks. We found that, when administered alone, neither intra-nigral AAV-α-synuclein nor intra-striatal rotenone caused sufficient nigrostriatal neurodegeneration to induce a significant motor impairment in their own right. However, when these were administered sequentially to the same rats, the interaction between the two Parkinsonian challenges significantly exacerbated nigrostriatal neurodegeneration which precipitated a pronounced impairment in motor function. These results indicate that exposing rats with a subclinical α-synuclein-induced pathology to the pesticide, rotenone, profoundly exacerbates their Parkinsonian neuropathology and dysfunction, and highlights the potential importance of this interaction in the etiology of, and in driving the pathogenesis of Parkinson's disease.
Copyright © 2016 Elsevier B.V. All rights reserved.

Entities:  

Keywords:  AAV; Animal model; Gene-environment; Parkinson’s disease; Rotenone; α-synuclein

Mesh:

Substances:

Year:  2016        PMID: 27585560     DOI: 10.1016/j.bbr.2016.08.056

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  8 in total

1.  [Effect of benzo(a)pyrene on dopaminergic neurons and α-synuclein in brain and its mechanism involved].

Authors:  Y Z Qi; H H Quan; W X Xu; Q R Li; H Zhou
Journal:  Beijing Da Xue Xue Bao Yi Xue Ban       Date:  2020-06-18

2.  Neonatal AAV delivery of alpha-synuclein induces pathology in the adult mouse brain.

Authors:  Marion Delenclos; Ayman H Faroqi; Mei Yue; Aishe Kurti; Monica Castanedes-Casey; Linda Rousseau; Virginia Phillips; Dennis W Dickson; John D Fryer; Pamela J McLean
Journal:  Acta Neuropathol Commun       Date:  2017-06-23       Impact factor: 7.801

Review 3.  Parkinson's Disease: From Pathogenesis to Pharmacogenomics.

Authors:  Ramón Cacabelos
Journal:  Int J Mol Sci       Date:  2017-03-04       Impact factor: 5.923

4.  Long noncoding RNA small nucleolar RNA host gene 12/microRNA-138-5p/nuclear factor I/B regulates neuronal apoptosis, inflammatory response, and oxidative stress in Parkinson's disease.

Authors:  Lei Yan; Lei Li; Jingan Lei
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  The Small Molecule Alpha-Synuclein Aggregator, FN075, Enhances Alpha-Synuclein Pathology in Subclinical AAV Rat Models.

Authors:  Rachel Kelly; Andrew G Cairns; Jörgen Ådén; Fredrik Almqvist; Alexis-Pierre Bemelmans; Emmanuel Brouillet; Tommy Patton; Declan P McKernan; Eilís Dowd
Journal:  Biomolecules       Date:  2021-11-12

Review 6.  Update on the application of mesenchymal stem cell-derived exosomes in the treatment of Parkinson's disease: A systematic review.

Authors:  Shu-Fen Liu; Lin-Yi Li; Jian-Long Zhuang; Mi-Mi Li; Li-Chao Ye; Xiang-Rong Chen; Shu Lin; Chun-Nuan Chen
Journal:  Front Neurol       Date:  2022-10-03       Impact factor: 4.086

Review 7.  Adult Endogenous Dopaminergic Neuroregeneration Against Parkinson's Disease: Ideal Animal Models?

Authors:  Yuganthini Vijayanathan; Siong Meng Lim; Maw Pin Tan; Fei Ting Lim; Abu Bakar Abdul Majeed; Kalavathy Ramasamy
Journal:  Neurotox Res       Date:  2020-11-03       Impact factor: 3.911

8.  Precision Medicine on the Fly: Using Drosophila to Decipher Gene-Environment Interactions in Parkinson's Disease.

Authors:  Souvarish Sarkar; Mel B Feany
Journal:  Toxicol Sci       Date:  2021-08-03       Impact factor: 4.109

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.